CytomX Therapeutics price to free cash flow CTMX

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 15.4×; Jul 2021
9-year median: 6.3×
9-year range: 3.6× to 206×
Peer median: 9.4×

CytomX Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2021, at 15.4×.

On the days it had one over the last 9 years, its median was 6.3×, from 3.6× in Aug 2017 to 206× in Apr 2021.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	15.4×	15.4×	206×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	5.5×	5.1×	8.6×
2017	5.5×	3.6×	5.9×

Against its peers

Companies in Drug Manufacturers - General nearest CytomX Therapeutics' size, closest first, today.

Company	Price to free cash flow
CTMXCytomX Therapeutics	n/m
ARVNArvinas	n/m
PBYIPuma Biotechnology	13.8×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
COLLCollegium Pharmaceutical	2.3×
ABUSArbutus Biopharma	n/m
AMPHAmphastar Pharmaceuticals	7.0×
NATRNatures Sunshine Products	11.8×
OMEROmeros	n/m
Peer median	9.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on CytomX Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.